Morgan Stanley Downgrades ResMed (RMD) to Underweight
More News related to RMD
- ResMed (RMD) Reports Mixed Q1 Earnings
- ResMed Inc. Announces Record Financial Results for the Quarter and Year Ended June 30, 2008
- ResMed to Webcast Fourth Quarter and Fiscal Year End Earnings Conference Call
- Morgan Stanley Downgrades ResMed (RMD) to Underweight
- ResMed (RMD) Could Goto $53 -Cramer
More News related to Downgrades
- Raymond James Downgrades 8 Restaurant Stocks Today
- Merrill Lynch Downgrades General Dynamics (GD) to Neutral
- Deutshe Bank Downgrades Cavium Networks (CAVM) to Hold
- Sandler O'Neill Downgrades Boston Private (BPFH) to Sell
- Raymond James Downgrades Hibbet Sports (HIBB) to Market Perform
Morgan Stanley downgrades ResMed (NYSE: RMD) from Equalweight to Underweight.
ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.
Related Categories
DowngradesStocks Mentioned
-0.71Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
